Focus Diagnostics, Inc. 10703 Progress Way Cypress, California 90630 USA

Establishment Registration No. 2023365

Contact Person

Michael J. Wagner, Esq. tel 714.220.1900 fax 714.995.6921 mwagner@focusdx.com

# Summary Date

January 29, 2007

Proprietary Name Generic Name Classification Predicate Devices

Plexus™MHerpeSelect®1 and 2 IgG   
Herpes Simplex Virus Types I and 2 Serological Assays   
Class II   
HerpeSelect 1 and 2 Immunoblot IgG   
HerpeSelect-1 ELISA IgG   
HerpeSelect-2 ELISA IgG

# Device Description

The Focus Diagnostics Plexus™HerpeSelect1 nd  IgGis amultiplexed mmoassay r qualitatively eteci n differentiating human IgG antibodies to HSV-1 and HSV-2.

# Intended Use

Focus Diagnostics' PlexusHerpeSelect®1and $2 ~ \mathrm { { I g G } }$ ue   an eT immunocompromised patients, for use by a point of care facility or for use with automated equipment.

# Test Principle

The F Dagosti PlexuHerpeSelecn Gus nten Bea uspenion hat contai ist HV Plexus™HerpeSelect®1 and $2 \mathrm { I g } \mathrm { G }$ is a three step procedure.

antibodies bind to the corresponding antigen beads.   
ycyconjga atantiuman gG Conjug dand he Conjg ind  the bouHV antibody (if present), and forms a Conjugate-HSV antibody-antigen bead sandwich.   
Fl C

# Performance Characteristics

# Summary of Studies (details below)

<table><tr><td rowspan=1 colspan=1>Study</td><td rowspan=1 colspan=1>PlexusHerpeSelect 1 IgGResults</td><td rowspan=1 colspan=1>PlexusHerpeSelect 2 IgGResults</td></tr><tr><td rowspan=1 colspan=1>Expectant Mothers (Indicated population)        Agreement with positivesAgreement with negatives</td><td rowspan=1 colspan=1>96.5%92.2%</td><td rowspan=1 colspan=1>94.3%95.5%</td></tr><tr><td rowspan=1 colspan=1>Sexually Active Adults (Indicated population)    Agreement with positivesAgreement with negatives</td><td rowspan=1 colspan=1>91.0%96.5%</td><td rowspan=1 colspan=1>96.3%97.4%</td></tr><tr><td rowspan=1 colspan=1>CDC HSV/CMV Panet                             Agreement with positivesAgreement with negatives</td><td rowspan=1 colspan=1>100%100%</td><td rowspan=1 colspan=1>100%100%</td></tr><tr><td rowspan=1 colspan=1>Low Prevalence Population                        Agreement with negatives</td><td rowspan=1 colspan=1>97.9%</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Cross-reactivity with CMV, EBV and VZV.     Cross-reactivity</td><td rowspan=1 colspan=1>0-5%</td><td rowspan=1 colspan=1>0-3%</td></tr><tr><td rowspan=1 colspan=1>Reproducibility                                     %CV of positives</td><td rowspan=1 colspan=1>≤10%</td><td rowspan=1 colspan=1>≤10%</td></tr></table>

# Reactivity with Expectant Mothers $\mathbf { \left( n = 3 0 0 \right) }$ ..

Focus $( \mathsf { n } = 1 5 0 )$ )and an external investigator $\mathbf { \tilde { n } } = 1 5 0 $ assessed the device's reactivity with sera from Expectant Mothers. The wy  y  asTxtv   y lay caoalnhe wecol he corUn aThe Herpeelec Pexu esults wee cpare he HerpeSelc LIA Ganhe HerpeSelct  LIA IG u Focus HerpeSelect 1 and 2 Immunoblot IgG as the reference method.

# HSV-1 Reactivity

The Focus HerpeSelect 1 Immunoblot IgG was: HSV-1 positive for 170 samples, HSV-1 negative with 128 samples, and HSV Common Antigen band positive for two samples.

The Plexus HerpeSelect 1 agreed with:   
$9 6 . 5 \%$ (164/170) of Immunoblot positives, and   
$9 2 . 2 \%$ (1 18/128) of Immunoblot negatives.   
The two Immunoblot HSv Common Antigen band positives were both negative in the Plexus.

# HSV-2 Reactivity

The Focus HerpeSelect 2 Immunoblot IgG was: HSV-2 positive for 122 samples, HSV-2 negative with 176 samples, and HSV Common Antigen band positive for two samples.

The Plexus HerpeSelect 2 agreed with:   
$9 4 . 3 \%$ (115/122) of Immunoblot positives, and   
$9 5 . 5 \%$ (168/176) of Immunoblot negatives.   
The two Immunoblot HSV Common Antigen band positives were both negative in the Plexus.

Plexus HerpeSelect 1 IgG Reactivity with Expectant Mothers $\mathrm { ( n = } 3 0 0 \mathrm { ) }$   

<table><tr><td rowspan=2 colspan=1>Lab</td><td rowspan=2 colspan=1>HerpeSelectImmunoblot</td><td rowspan=1 colspan=3>Plexus</td><td rowspan=1 colspan=2>Plexus HerpeSelect-I</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>HerpeSelect-1 ELISA</td></tr><tr><td rowspan=1 colspan=1>&quot;</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>92.9% (78/84)95%C185.1-97.3%</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>92.9% (78/84)95%C1 85.1-97.3%</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>100% (86/86)95%C1 95.8-100%</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>100% (86/86)95%C1 95.8-100%</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>96.5% (164/170)95%CI 92.5-98.7%</td><td rowspan=1 colspan=1>170</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>96.5% (164/170)95%CI 92.5-98.7%</td></tr><tr><td rowspan=1 colspan=1>Site I</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>92.4% (61/66)95%CI 83.2-97.5%</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>89.4% (59/66)95%C1 79.4-95.6%</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>91.9% (57/62)95%CI 82.2-97.3%</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>95.2% (59/62)95%C1 86.5-99.0%</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>92.2% (118/128)95%CI 86.1-96.2%</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>92.2% (118/128)95%C1 86.1-96.2%</td></tr><tr><td rowspan=1 colspan=1>Site I</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr></table>

'lexus HerpeSelect 2 IgG Reactivity with Expectant Mothers $( \mathbf { n } = 3 0 0 )$   

<table><tr><td rowspan=2 colspan=1>Lab</td><td rowspan=2 colspan=1>Herpe-SelectImmunoblot</td><td rowspan=1 colspan=5>Plexus HerpeSelect-2</td><td rowspan=1 colspan=5>HerpeSelect-2 ELISA</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Site I</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>93.3% (56/60)95%CI 83.8-98.2%</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>96.7% (58/60)95%C188.5-99.6%</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>95.2% (59/62)95%CI 86.5-99.0%</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>98.4% (61/62)95%C191.3-100%</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>94.3% (115/122)95%CI 88.5-97.7%</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>97.5% (119/122)95%C193.0-99.5%</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>97.8% (88/90)95%CI 92.2-99.7%</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>95.6% (86/90)95%C1 89.0-98.8%</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>93.0% (80/86)95%CI 85.4-97.4%</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>93.0% (80/86)95%C1 85.4-97.4%</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>176</td><td rowspan=1 colspan=1>168</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>95.5% (168/176)95%CI 91.2-98.0%</td><td rowspan=1 colspan=1>176</td><td rowspan=1 colspan=1>166</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>94.3% (166/176)95%CI 89.8-97.2%</td></tr><tr><td rowspan=1 colspan=1>Site I</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr></table>

# Reactivity with Sexually Active Adults $( \mathbf { n } = 3 0 0 )$

Focus $( \mathsf { n } = 1 5 0 )$ and an external investigator $\mathit { \Omega } _ { \mathrm { ~ n ~ } } ^ { \prime } = 1 5 0 \mathit { \check { \Psi } } ,$ assessed the device's reactivity with sera from sexually active adults. The  ly  he y  asxt acClnc T HerpeSelect Pexus results were compared t the HerpeSelct ELISA IGand he HerpeSelect  ELISA IgG us the Focus HerpeSelect 1 and 2 Immunoblot IgG as the reference method.

# HSV-1 Reactivity

The Focus HerpeSelect 1 Immunoblot IgG was: HSV-1 positive for 157 samples, HSV-1 negative with 142 samples, and HSV Common Antigen band positive for one sample.

The Plexus HerpeSelect 1 agreed with:   
$9 1 . 0 \%$ (142/156) of Immunoblot positives (one sample was not run on the Plexus device), and $9 6 . 5 \%$ (137/142) of Immunoblot negatives.

# HSV-2 Reactivity

The Focus HerpeSelect 2 Immunoblot IgG was: HSV-2 positive for 109 samples, HSV-2 negative with 190 samples, and HSV Common Antigen band positive for one sample.

The Plexus HerpeSelect 2 agreed with:   
$9 6 . 3 \%$ (105/109) of Immunoblot positives, and   
$9 7 . 4 \%$ (184/189) of Immunoblot negatives (one sample was not run on the Plexus device).

Plexus HerpeSelect 1 IgG Reactivity with Sexually Active Adults $\mathbf { \left( n = 3 0 0 \right) }$   

<table><tr><td rowspan=2 colspan=1>Lab</td><td rowspan=2 colspan=1>HerpeSelectImmunoblot</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Plexus</td><td rowspan=1 colspan=2>Plexus HerpeSelect-1</td><td rowspan=1 colspan=5>HerpeSelect-1 ELISA</td></tr><tr><td rowspan=1 colspan=1>&quot;</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>91.5% (65/71)95%C1 82.5-96.8%</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>95.8% (68/71)95%C1 88.1-99.1%</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>85*</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>90.6% (77/85)95%C1 82.3-95.9%</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>93.0% (80/86)95%CI 85.4-97.4%</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>91.0% (142/156)95%C1 85.4-95.0%</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>93.6% (147/157)95%CI 88.6-96.9%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>98.7% (78/79)95%CI 93.1-100%</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>97.5% (77/79)95%CI 91.2-99.7%</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>93.7% (59/63)95%CI 84.5-98.2%</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>95.2% (60/63)95%CI 86.7-99.0%</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>96.5% (137/142)95%CI 92.0-98.9%</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>96.5% (137/142)95%C1 92.0-98.9%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr></table>

Plexus HerpeSelect 2 IgG Reactivity with Sexually Active Adults $( \mathbf { n } = 3 0 0 )$   

<table><tr><td rowspan=2 colspan=1>Lab</td><td rowspan=2 colspan=1>HerpeSelectImmunoblot</td><td rowspan=1 colspan=5>Plexus HerpeSelect-2</td><td rowspan=1 colspan=5>HerpeSelect-2 ELISA</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>91.5% (43/47)95%CI 79.6-97.6%</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>97.9% (46/47)95%C1 88.7.99.9%</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>100%(62/62)95%C1 94.2-100%</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>98.4%(61/62)95%C1 91.3-100%</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>96.3% (105/109)95%C1 90.9-99.0%</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>98.2% (107/109)95%C1 93.5-99.8%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>97.1% (100/103)95%C1 91.7-99.4%</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>99.0% (102/103)95%CI 94.7-100%</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>86*</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>97.7% (84/86)95%C191.8-99.7%</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>96.6% (84/87)95%CI 90.3-99.3%</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>189</td><td rowspan=1 colspan=1>184</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>97.4% (184/189)95%CI 93.9-99.1%</td><td rowspan=1 colspan=1>190</td><td rowspan=1 colspan=1>186</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>97.9% (186/190)95%CI 94.7-99.4%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Focus</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Combined Labs</td><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr></table>

# Agreement with CDC Panel $\mathbf { \left( n = 1 0 0 \right) }$ .

The o   p      Dhe p  a panel. This does not imply an endorsement of the assay by the CDC.

iiv -iv iv 54 HSV-1 positive and 36 HSV-2 positive specimens.

# Determination of positive and negative samples

Of the 54 HSV-1 positive samples, the HerpeSelect® Plexus IgG correctly identified $100 \%$ (54/54).   
Of the 36 HSV-2 positive samples, the HerpeSelect® Plexus IgG correctly identified $100 \%$ (36/36).   
Of the 22 double positive samples, the HerpeSelect® Plexus IgG correctly identified $100 \%$ (22/22).   
Of the 32 double negative samples, the HerpeSelect® Plexus IgG correctly identified $100 \%$ (32/32).

Agreement with CDC Panel $\bf ( n = 1 0 0 )$   

<table><tr><td rowspan=2 colspan=1>SampleType</td><td rowspan=1 colspan=2>CDC Result</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=4>HerpeSelect-1 Plexus Results</td><td rowspan=1 colspan=4>HerpeSelect-2 Plexus Results</td></tr><tr><td rowspan=1 colspan=1>HSV1</td><td rowspan=1 colspan=1>HSV2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>HSV-1Positive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>100% (32/32)95%C1 89.1-100%</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (32/32)95%CI 89.1-100%</td></tr><tr><td rowspan=1 colspan=1>HSV-2Positive</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (14/14)95%CI 76.8-100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>100% (14/14)95%C1 76.8-100%</td></tr><tr><td rowspan=1 colspan=1>DualPositive</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>100% (22/22)95%CI 84.6-100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>100% (22/22)95%CI 84.6-100%</td></tr><tr><td rowspan=1 colspan=1>DualNegative</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (32/32)95%C1 89.1-100%</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (32/32)95%CI 89.1-100%</td></tr></table>

# CDC Panel Reproducibility

Apa  cr he Fou  Heecn Peu Gn paired HSV-1 positive and HSV-2 negative $( 1 0 0 \% )$ , 7 out of 7 paired HSV-2 positive and HSV-1 negative $( 1 0 0 \% )$ , 11 out of 11 paired double-positive $( 1 0 0 \% )$ and 16 out of 16 paired double-negative $( 1 0 0 \% )$ samples.

# Reactivity with a Low Prevalence Population $( \mathbf { n } = 7 7 )$ EPY

Focus $( \mathfrak { n } = 7 7$ s the devic' reaciviy with s from  ow prevalenc poplation.Fous seec ro pants herevi  nd t c  patnt piThe  we  , ivan masked The HerpeSelectPeu results were compare  the Focus HerpeSelect  and Immobo IgG.

# HSV-1 Reactivity

The Focus HerpeSelect  Immoblot IgG was: HSV-1 positive or 28 mples, HSV-1 negative with 7 smpes, an HSV Common Antigen band positive for two samples.

The Plexus HerpeSelect 1 agreed with: $9 6 . 4 \%$ (27/28) of Immunoblot positives (one HSV-1 Immunoblot positive wa: equivocal in the Plexus device), and $9 7 . 9 \%$ (46/47) of Immunoblot negatives (one HSV-1 Immunoblot negative was positive in the Plexus device).

One Imoblot HV Common Antigen band positive was equivocal in the Plexus, and the other sample was Plxus negative.

# HSV-2 Reactivity

TheF Herlelot I asHSV ss, HS-ive ie HV Common Antigen band positive for two samples.

The Plexus HerpeSelect 2 agreed with: $7 5 . 0 \%$ (3/4) of Immunoblot positives (one HSV-1 Immunoblot positive was equivocal in the Plexus device), and $100 \%$ (71/71) of Immunoblot negatives (one HSV-1 Immunoblot negative was positive in the Plexus device). Both Immunoblot HSV Common Antigen band positives were negative in the Plexus.

Reactivity with Low Prevalence Population $( \mathbf { n } = 7 7 )$ E   

<table><tr><td rowspan=2 colspan=1>HerpeSelectImmunoblot</td><td rowspan=1 colspan=5>Plexus HerpeSelect-1</td><td rowspan=1 colspan=5>Plexus HerpeSelect-2</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>% Agreement</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>96.4% (27/28)95%CI81.6-99.9%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>75.0% (3/4)95%C1 19.4-99.4%</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>97.9% (46/47)95%C1 88.7-99.9%</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100% (71/71)95%C1 94.9-100%</td></tr><tr><td rowspan=1 colspan=1>Com</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td></tr></table>

# Cross-reactivity $\mathbf { ( n = 5 1 ) }$

Focus assessed cross-reactivity with two groups of samples: a "HSV ELISA dual negative" group $\left( \mathrm { n } { = } 3 7 \right)$ ), and a "HSV ELISA mixed sero-reactivity" group $( \mathrm { n } { = } 1 4 )$

The HSV ELISA dual negative group $\left( \mathsf { n } \mathrm { = } 3 7 \right)$ included samples that were sero-negative with both the HerpeSelect-1 ELISA   
IgG and HerpeSelect 2 ELISA $\mathrm { I g G }$ , and were sero-positive by at least one of   
a FDA cleared CMV ELISA IgG $( \mathtt { n } = 1 8 )$   
a home brerw VZV ACIF $\mathrm { ( n = } 3 2$   
a FDA cleared EBV VCA IgG $\scriptstyle ( \ n = 3 1$   
The Plexus HerpeSelect®1 and $2 \mathrm { I g } \mathrm { G }$ was HSV-1 negative with al but one of the HSV ELISA dual negatives, and equivocal   
with one sample (the one sample was $\mathrm { C M V + V Z V + }$ and $\mathrm { E B V + }$   
The Plexus HerpeSelect®1 and $2 \mathrm { I g } \mathrm { G }$ was HSV-2 negative with all but one of the HSV ELISA dual negatives, and equivocal   
with one sample (the one sample was CMV- ${ \mathrm { V Z V } } +$ and $\mathrm { E B V + }$ i The HSV ELISA mixed reactivity group $\scriptstyle ( \ n = 1 4 )$ included samples that were sero-positive with either the HerpeSelect-1 ELISA IgG or HerpeSelect 2 ELISA IgG, and were sero-positive by at least one of   
a FDA cleared CMV ELISA IgG (HSV-1 neg ${ \mathfrak { n } } = 2$ , HSV-2 neg $\boldsymbol { \mathrm { n } } = 9$   
a home brew VZV ACIF (HSV-1 neg $\mathfrak { n } = \mathfrak { l }$ , HSV-2 neg $\mathfrak { n } = 2$   
a FDA cleared EBV VCA IgG (HSV-1 neg $\mathbf { n } = \mathbf { l }$ , HSV-2 neg $\boldsymbol { \mathrm { n } } = \boldsymbol { \mathrm { 0 } }$   
The Plexus HerpeSelect®1 and $2 \mathrm { I g } \mathrm { G }$ was HSV-1 negative with all of the HSV-1 ELISA negatives in the mixed reactivity group.   
The Plexus HerpeSelec $\textsuperscript { t }$ l and $2 \mathrm { l g } \mathrm { G }$ was HSV-2 negative with all of the HSV-2 ELISA negatives in the mixed reactivity group.

Cross-reactivity $\mathbf { ( n = 5 1 ) }$   

<table><tr><td rowspan=2 colspan=1>Cross-reactant</td><td rowspan=2 colspan=1>HSVELISAs</td><td rowspan=1 colspan=5>HerpeSelect-1Plexus</td><td rowspan=1 colspan=5>HerpeSelect-2 Plexus</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv*</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>%Pos</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Eqv+</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>%Pos</td></tr><tr><td rowspan=3 colspan=1>CMV IgG +</td><td rowspan=1 colspan=1>Dual Neg</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5.6% (1/18)95%C1 0.1-27.3%</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/18)95%C1 0.0-18.5%</td></tr><tr><td rowspan=1 colspan=1>+/-or-1+</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/2)95%C1 0.0-84.2%</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/9)95%CI 0.0-33.6%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5.0% (1/20)95%C1 0.1-24.9%</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/27)95%CI 0.0-12.8%</td></tr><tr><td rowspan=3 colspan=1>VZV IgG +</td><td rowspan=1 colspan=1>Dual Neg</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.1% (1/32)95%CI 0.1-16.2%</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.1% (1/32)95%C1 0.1-16.2%</td></tr><tr><td rowspan=1 colspan=1>+/-or-/1+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/1)na</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/2)95%CI 0.0-84.2%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.0% (1/33)95%CI 0.1-15.8%</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2.9% (1/34)95%C1 0.1-15.3%</td></tr><tr><td rowspan=3 colspan=1>EBV IgG +</td><td rowspan=1 colspan=1>Dual Neg</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.2% (1/31)95%C1 0.1-16.7%</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.2% (1/31)95%C10.1-16.7%</td></tr><tr><td rowspan=1 colspan=1>+1-or-1+</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0% (0/1)na</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>na</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.1% (1/32)95%CI 0.1-16.2%</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3.2% (1/31)95%CI 0.1-16.7%</td></tr></table>

ZV. $\dagger$ The HerpeSelect -2 Plexus was equivocal with one sample, and the sample was IgG positive for VZV and EBV.

# Inter-laboratory Reproducibility and Inter/Intra-assay Reproducibility

Fl calnb c tested eleven samples in triplicate on five different days.

Inter-laboratory Reproducibility and Inter/Intra-assay Reproducibilitya   

<table><tr><td rowspan=3 colspan=1>Sample</td><td rowspan=1 colspan=5>HerpeSelect 1 Plexus IgG Results</td><td rowspan=1 colspan=5>HerpeSelect 2 Plexus IgG Results</td></tr><tr><td rowspan=1 colspan=3>Intra- and Inter-assay</td><td rowspan=1 colspan=2>Inter-Lab</td><td rowspan=1 colspan=3>Intra- and Inter-assay</td><td rowspan=1 colspan=2>Inter-Lab</td></tr><tr><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Intra-assay% CV</td><td rowspan=1 colspan=1>Inter-assay% CV</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Intra-assay% CV</td><td rowspan=1 colspan=1>Inter-assay% CV</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>% CV</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>4.93</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>4.94</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>3.88</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>3.87</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4.24</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>4.22</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>4.90</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>4.89</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3.87</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>3.86</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.36</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>3.35</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3.27</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>3.25</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>4.56</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>4.55</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3.24</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>3.22</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.55</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>2.54</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.04</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>3.02</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.71</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>2.70</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>12b</td><td rowspan=1 colspan=1>2.13</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>2.13</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.87</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>1.87</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>28.3</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>22.6</td></tr><tr><td rowspan=1 colspan=1>I0c</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>213.1</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>59.0</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>11.4</td><td rowspan=1 colspan=1>334.2</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>103.8</td></tr><tr><td rowspan=1 colspan=1>10d</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>15.8</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>41.7</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>38.3</td></tr><tr><td rowspan=1 colspan=1>.7</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>16.3</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>23.7</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>17.3</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>16.0</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>39.8</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>38.1</td></tr></table>

Control was run in those wells since the indices were about 1.9 for both $\mathfrak { g } \mathrm { G } \mathfrak { l }$ and $\mathfrak { g } \mathrm { G } 2$ ) did not have sufficient volume to be sent to investigators. about 2.7 for both $\mathsf { g G l }$ and $\mathtt { g G 2 }$ . about 2.7 for both $\mathrm { g G } 1$ and $\mathrm { \& } \mathrm { \ b { G } } 2$ .

# Inter-Lot Reproducibility

in triplicate. Each lot had a different set of $\mathrm { g } \mathsf { G } - \mathsf { I }$ and $\mathbf { g } \mathbf { G } 2$ beads, a different lot of conjugate (made from 2 different stock of the studies are summarized in the tables below:

Inter-lot Reproducibility   

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=1 colspan=2>HSV-1</td><td rowspan=1 colspan=2>HSV-2</td></tr><tr><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Inter-Lot%CV</td><td rowspan=1 colspan=1>MeanIndex</td><td rowspan=1 colspan=1>Inter-Lot%CV</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>5.20</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>3.90</td><td rowspan=1 colspan=1>12.8</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4.36</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>4.76</td><td rowspan=1 colspan=1>9.2</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3.60</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>3.19</td><td rowspan=1 colspan=1>9.3</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3.29</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>2.54</td><td rowspan=1 colspan=1>6.4</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>3.23</td><td rowspan=1 colspan=1>11.3</td><td rowspan=1 colspan=1>4.45</td><td rowspan=1 colspan=1>9.4</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.14</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>2.73</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>12/14*</td><td rowspan=1 colspan=1>2.22</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>1.86</td><td rowspan=1 colspan=1>7.8</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>17.0</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>50.9</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>31.3</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>21.8</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>45.6</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>24.9</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>50.6</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>26.9</td></tr></table>

and 13 did not have sufficient volume to be sent to investigators.

Michael J. Wagner, Esq. Regulatory Counsel Focus Diagnostics, Inc. 10703 Progress Way Cypress, CA 90630

Re: k062543 Trade/Device Name: HerpeSelect 1 and 2 Plexus IgG Regulation Number: 21 CFR 866.3305 Regulation Name: Herpes simplex virus serological reagents Regulatory Class: Class II Product Code: MXJ, MYF Dated: January 15, 2007 Received: January 17, 2007

Dear Mr. Wagner:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours, fall, ation

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

Enclosure

Device Name:

PlexusHerpeSelect®1 and $2 \ \mathrm { I g } \mathrm { G }$

Indications for Use:

Focus Diagnostics' Plexus™HerpeSelect $\textsuperscript { \textregistered 1 }$ and $2 \ \mathrm { I g G }$ is intended for qualitatively detecting the presence or absence of human IgG class antibodies to HSV-1 and HSV-2 in human sera. The test is indicated for testing sexually active adults or expectant mothers for aiding in the presumptive diagnosis of HSV-1 and HSV-2 infection. The predictive value of a positive or negative result depends on the population's prevalence and the pretest likelihood of HSV-1 and HSV-2 infection. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, for testing of immunocompromised patients, for use by a point of care facility or for use with automated equipment.